WO2004002435A2 - Utilisation d'isoflavones pour favoriser l'amincissement - Google Patents
Utilisation d'isoflavones pour favoriser l'amincissement Download PDFInfo
- Publication number
- WO2004002435A2 WO2004002435A2 PCT/FR2003/001956 FR0301956W WO2004002435A2 WO 2004002435 A2 WO2004002435 A2 WO 2004002435A2 FR 0301956 W FR0301956 W FR 0301956W WO 2004002435 A2 WO2004002435 A2 WO 2004002435A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- isoflavones
- aglycone
- use according
- treatment method
- glycosylated form
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Definitions
- isoflavones for the preparation of topical compositions useful for promoting thinning, and associated cosmetic treatment method.
- the present invention relates to the use of isoflavones for the preparation of topical compositions useful for promoting thinning and to the associated cosmetic treatment method.
- Thinning in the context of the present invention preferably involves combating localized overweight.
- adipose tissue represents 20 to 30% of body weight in women and 10 to 15% in men.
- Subcutaneous fat is twice as thick in women as in men.
- fat accumulates around and above the belt (android distribution, metabolic risk factor) and below the belt, in the gluteo-femoral region in women (gynoid distribution, not correlated with vascular risk).
- One of the characteristics of this fat accumulated at the bottom of the body is that it is difficult to mobilize. It is intended to meet the energy needs of reproduction (pregnancy and, above all, breastfeeding) and thus constitutes the most important energy reservoir of the organism.
- adipocytes are spherical cells are the intracellular space is filled with a large vacuole filled with triglycerides.
- Fat cells can change volume quickly. In fact, depending on the circumstances, these cells can reach 40 ⁇ m to 120 ⁇ m in diameter, which corresponds to a 27-fold increase in volume. In some extreme cases, this increase can be up to 40 times.
- the adipocyte is the main energy player in the body since it is able to store (uptake or lipogenesis) or, conversely, to quickly mobilize (lipolysis) triglycerides, major energy sources in the body.
- Lipogenesis involves the synthesis of triacylglycerols which results from the esterification of glycerol-3-phosphate by activated fatty acids; conversely, lipolysis corresponds to the hydrolysis of the stored triacylglycerols, in glycerol and in fatty acids.
- Different mechanisms have been brought to light, which control lipolysis and lipogenesis, which involve, for example, receptors such as alpha-2 and / or beta-1 and -2 receptors, adenosine type A1 receptors, prostaglandin E2, Y2 type YY and the neuropeptide NPY, but also sex hormones.
- Lipolytics Caffeine found in many plants: green tea, guarana seeds: inhibits phosphodieterase, thus ensuring an optimal intracellular cAMP level, stimulates ⁇ receptors and inhibits lipoprotein lipase; Rhodysterol (extracted from a red algae): activates the ⁇ receptors and promotes the penetration of caffeine; Palmitoyl-carnitine: accelerates the combustion of fatty acids, improving their uptake by the mitochondria;
- the alpha and gamma bioactives (respectively from a marine bacterium and a fungus): block the ⁇ 2 and NPY receptors;
- Escin and ginkgo biloba ⁇ 2 blockers; Sphingosine: limits the penetration of glucose
- Andiroba triterpenes
- Carcina Cambogia block the transformation of pre-adipocytes into adipocytes
- Rutin (extracted from Ruta graveolens): isolates glucose and prevents its association with free fatty acids.
- disinfiltrating active agents and veinotonic agents which are often associated with slimming active agents.
- formulations comprising these known slimming active agents can be supplemented by restructuring and smoothing active agents which fight against sagging skin.
- Patent application WO01 / 64177 discloses the use of a composition comprising a flavone, an isoflavone, or glycosyl and optionally a substance stimulating and / or depolarizing the nerve fibers for cosmetic treatments of cellulite or of firming of the skin.
- cellulite is defined as a localized metabolic disorder of the subcutaneous tissues which causes an alteration of the forms of the body.
- the overweight is due to an enlargement or hyperplasia of the adipocytes (increase in lipogenesis), decrease in lipolysis.
- the differentiation between cellulite and thinning also appears in view of the fact that cellulite affects the dermis (subcutaneous tissue) of women only while overweight (adipocytes) affects all of the two sexes.
- cellulite appears in women even without overweight; it is a dermis / hypodermis architecture problem.
- Patent application EP 829261 relates to compositions comprising isoflavones for their weight reducing effect by the degradation of fats accumulated in fat cells.
- the topical mode of administration is not mentioned in this patent application.
- the present invention thus relates to the use of isoflavones for the preparation of topical compositions useful for promoting thinning and to the associated cosmetic treatment method.
- the “isoflavones” which can be used according to the present invention can be natural substances extracted from natural products, in particular from plants such as soya, clover, lupine, apple seeds, etc.
- the topical compositions according to the present invention contain, as isoflavones a mixture of different isoflavones, but they can also be present in pure form in the context of the present invention.
- the aglycone forms of isoflavones and the glycosylated forms of the latter. These various forms are most often found in a mixture. They are illustrated by the following formulas. Aglycone forms, of formula
- R ' x represents a hydrogen atom or a hydroxy group
- R' 2 represents a hydrogen atom or a methoxy group
- R ' 3 represents a hydroxy group
- R' ⁇ , R ' 2 and R' 3 represent:
- R ' 4 represents a hydrogen atom or a hydroxy group
- R' 5 represents a hydrogen atom or a methoxy group
- R ' 6 represents a hydrogen atom
- R ' 4 , R' 5 and R ' 6 represent
- isoflavones are the most abundant in nature. Natural isoflavones such as genistein (1), daidzein or glycitein are preferred as isoflavones.
- the genistein or 4,5,7-trihydroxyisoflavone which can be used according to the present invention can be a product of plant origin and in particular of soybean, containing 85 to 90% by weight of genistein, in particular the product marketed by the company Buckton Scott under the name "genistein titrated to
- the isoflavones can be used alone or as a mixture in the context of the present invention.
- Topical application of a composition of one or more isoflavones can be particularly advantageous in pregnant women or women with delivered less than 6 months ago.
- the present invention thus also relates to a cosmetic treatment method for promoting thinning and in particular for combating overweight localized in pregnant women or women who have given birth less than 6 months ago.
- one of the advantages of compositions which can be used in the context of the present invention is that it does not require the presence of alcohol for the formulation, which is contraindicated for pregnant and breastfeeding women because of its toxicity.
- caffeine a very commonly used slimming active ingredient, requires solubilization in alcohol, which is thus avoided in the context of the present invention.
- cosmetic treatment to combat localized overweight method is meant, according to the present invention, the implementation of a cosmetic treatment making it possible to visibly measure the action described above.
- a topical composition comprising one or more Isoflavones used according to the invention can be applied to the areas of the skin capable of forming these localized overweight, namely areas where these overloads are already formed or in the course of formation.
- a composition containing genistein which can be used in the context of the present invention may contain between 0.0085 and 8.5% of genistein by weight relative to the total weight of the composition , or for a solution containing 85 to 90% by weight of genistein, between 0.01 and 10% by weight of this solution relative to the total weight of the composition.
- composition containing one or more isoflavones which can be used in the context of the present invention may contain between 0.01 and 10% by weight of isoflavone (s) relative to the total weight of the composition , and preferably from 0.1 to 3%.
- composition which allows the implementation of the invention comprises a cosmetically acceptable support, that is to say a support compatible with the skin and can be in all the galenical forms normally used for a topical application, in particular in the form of an aqueous, hydroalcoholic or oily solution, an oil-in-water or water-in-oil or multiple emulsion, an aqueous or oily gel, a liquid, pasty or solid anhydrous product, a dispersion of oil in an aqueous phase using spherules, these spherules possibly being polymeric nanoparticles such as nanospheres and nanocapsules or better lipid vesicles ionic and / or non-ionic type.
- a cosmetically acceptable support that is to say a support compatible with the skin and can be in all the galenical forms normally used for a topical application, in particular in the form of an aqueous, hydroalcoholic or oily solution, an oil-in-water or water-in-oil or multiple emul
- This composition can be more or less fluid and have the appearance of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a foam. or a gel.
- It can optionally be applied to the skin in the form of an aerosol. It can also be in solid form, and for example in the form of a stick.
- composition of the invention can also contain the usual adjuvants in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, chelating agents, absorbents of odor and coloring matter.
- adjuvants in the cosmetic field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, preservatives, antioxidants, solvents, perfumes, chelating agents, absorbents of odor and coloring matter.
- the amounts of these various adjuvants are those conventionally used in the fields under consideration, and for example from 0.01 to 20% of the total weight of the composition.
- These adjuvants depending on their nature, can be introduced into the fatty phase, into the aqueous phase, into the lipid vesicles and or into the nanoparticles.
- the proportion of the fatty phase can range from 5 to 80% by weight, and preferably from 5 to 50% of the total weight of the composition.
- the oils, emulsifiers and coemulsifiers used in the composition in the form of an emulsion are chosen from those conventionally used in the field under consideration.
- the emulsifier and the coemulsifier are present in the composition in a proportion ranging from 0.3 to 30% by weight, and preferably from 0.5 to 20% of the total weight of the composition.
- oils usable in the compositions for implementing the invention mention may be made of mineral oils, oils of plant origin
- oils of animal origin oils, synthetic oils, silicone oils and fluorinated oils
- Fat can also be used as fatty alcohols (cetyl alcohol), fatty acids, waxes (beeswax).
- emulsifiers and coemulsifiers which can be used in the invention, there may be mentioned, for example, fatty acid and polyethylene glycol esters such as PEG-40 stearate, PEG-100 stearate, fatty acid and polyol esters such as glyceryl stearate and sorbitan tristearate.
- hydrophilic gelling agents mention may in particular be made of carboxyvinyl polymers (carbomers), acrylic copolymers such as acrylate / alkyl acrylate copolymers, polyacrylamides, polysaccharides, natural gums and clays, and, as lipophilic gelling agents, cite modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.
- carboxyvinyl polymers carboxyvinyl polymers
- acrylic copolymers such as acrylate / alkyl acrylate copolymers
- polyacrylamides polysaccharides
- natural gums and clays and, as lipophilic gelling agents, cite modified clays such as bentones, metal salts of fatty acids, hydrophobic silica and polyethylenes.
- composition used according to the invention may contain other active ingredients with slimming action such as lipolytics and liporeducing agents as described in the introduction.
- the invention thus relates to the use of isoflavones for the preparation of topical compositions useful for promoting thinning and in particular for combating localized overweight, characterized in that one or more isoflavones are applied simultaneously, separately or spread over time, as well as one or two slimming active agents of lipolytic type and / or one or two active agents slimming products of the liporeducing type.
- the slimming active ingredient of the lipolytic type can be chosen from: caffeine, rhodysterol, palmitoyl-carnitine, bioactives alpha and gamma, escin, ginkgo biloba and sphingosine.
- the slimming active ingredient of the liporeducing type can be chosen from: andiroba, Garcinia Cambogia, rutin.
- One or two or two disinfiltrating or veinotonic active agents can also be applied simultaneously, separately or over time, in addition to the application of the composition used according to the invention.
- the disinfiltrating or veinotonic active ingredients can be chosen from: viburnum, ivy, arnica, pisolle, wild pansy, Fucus vesiculosus, ruscus, ginkgo biloba and escin.
- composition used according to the invention can also comprise other active agents such as: - An extract of sophora japonica flowers: this extract is rich in flavonoids (anti-radical) and in rutin. This active ingredient promotes microcirculation, facilitating and activating the drainage and disinfiltration of tissues; - Centella asiatica extract: Centella extract, plant native to East Africa and
- This active ingredient contains terpenes (asiaticosides, asiatica acid and madecassic acid), with draining, disinfiltrating and firming properties on the tissues. It is used in particular in slimming products but also in anti-stretch mark, anti-wrinkle and healing products; 0 to 5% of centella extract can thus be present in a slimming composition; "Hydrolyzed Soy Protein”: soy protein which is an elastoregulator.
- soy peptides can be any peptide obtained by hydrolysis of proteins extracted from soy, according to operating conditions known to those skilled in the art, in other words any soy protein hydrolyzate.
- soy peptides which are described in patent application WO 00/19974, are particularly suitable for being introduced into the compositions used in the context of the present invention.
- This active ingredient allows the restoration of cell renewal mechanisms, activates the synthesis of structural elements of the extracellular matrix and has a restructuring, regenerating and firming action; 0 to 5% of soy protein can thus be present in a slimming composition; anti-aging active ingredients, among which mention may be made of avocado furans, retinol and its derivatives, vitamin C or soy unsaponifiables, etc.
- Such a composition can contain from 0.01 to 20% of Sophora Japonica flower extract.
- Example 1 Restructuring gel
- Sophora Japonica Flo er Extract 0.01 to 20
- Soy extract rich in isoflavones obtained by physical extraction isooflavones obtained by physical extraction:
- Isoflavone mixture at least 30%
- Genistein / daidzine / glycitin ratio 1.3 / 1.0 / 0.3
- Example 10 Summary of the test for using the restructuring gel according to Example 1
- the restructuring gel studied was applied 2 times a day on average (morning and evening), for 1 to 2 months, on the body (thighs, hips, stomach and buttocks in particular), by consumers, at their home, under normal conditions of use, instead of the one they generally use.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002491150A CA2491150A1 (fr) | 2002-06-27 | 2003-06-25 | Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement, et methode de traitement cosmetique associee |
EP03761638A EP1515696B1 (fr) | 2002-06-27 | 2003-06-25 | Utilisation d'isoflavones pour favoriser l'amincissement |
AU2003264673A AU2003264673A1 (en) | 2002-06-27 | 2003-06-25 | Use of isoflavones for promoting slimming |
US10/519,096 US20050256061A1 (en) | 2002-06-27 | 2003-06-25 | Use of isoflavones for preparing topical compositions for promoting slimming, and related cosmetic treatment method |
DE60322898T DE60322898D1 (de) | 2002-06-27 | 2003-06-25 | Verwendung von isoflavonen zur förderung des schlankheitseffekts |
MXPA05000073A MXPA05000073A (es) | 2002-06-27 | 2003-06-25 | Uso de isoflavonas para preparar composiciones topicas para promover el adelgazamiento, y metodo de tratamiento cosmetico relacionado. |
HK05108441A HK1074404A1 (en) | 2002-06-27 | 2005-09-23 | Use of isoflavones for promoting slimming |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR02/07995 | 2002-06-27 | ||
FR0207995A FR2841470B1 (fr) | 2002-06-27 | 2002-06-27 | Utilisation d'isoflavones pour la preparation de compositions topiques utiles pour favoriser l'amincissement et methode de traitement cosmetique associee |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004002435A2 true WO2004002435A2 (fr) | 2004-01-08 |
WO2004002435A3 WO2004002435A3 (fr) | 2004-05-13 |
Family
ID=29724931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/001956 WO2004002435A2 (fr) | 2002-06-27 | 2003-06-25 | Utilisation d'isoflavones pour favoriser l'amincissement |
Country Status (11)
Country | Link |
---|---|
US (1) | US20050256061A1 (fr) |
EP (1) | EP1515696B1 (fr) |
CN (1) | CN1671354A (fr) |
AU (1) | AU2003264673A1 (fr) |
CA (1) | CA2491150A1 (fr) |
DE (1) | DE60322898D1 (fr) |
ES (1) | ES2311730T3 (fr) |
FR (1) | FR2841470B1 (fr) |
HK (1) | HK1074404A1 (fr) |
MX (1) | MXPA05000073A (fr) |
WO (1) | WO2004002435A2 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2870743A1 (fr) * | 2005-03-21 | 2005-12-02 | Expanscience Sa Lab | Utilisation d'alkyle furannes pour la preparation d'un medicament destine au traitement de l'obesite et pour le traitement cosmetique de la surcharge ponderale |
FR2870740A1 (fr) * | 2005-03-21 | 2005-12-02 | Expanscience Sa Lab | Utilisation d'alkyle furannes pour le traitement cosmetique de la cellulite |
WO2005117827A1 (fr) * | 2004-05-28 | 2005-12-15 | Laboratoires Expanscience | Utilisation d’alkyle furannes pour le traitement cosmetique de la cellulite |
WO2005117857A1 (fr) * | 2004-05-28 | 2005-12-15 | Laboratoires Expanscience | Utilisation d’alkyle furannes pour la preparation d'un medicament destine au traitement de l’obesite et pour le traitement cosmetique de la surcharge ponderale |
WO2006076240A2 (fr) * | 2005-01-10 | 2006-07-20 | The Procter & Gamble Company | Compositions, produits et methodes destines a combattre la surcharge ponderale chez un mammifere |
WO2006117392A3 (fr) * | 2005-05-04 | 2007-03-22 | Lancaster Group Gmbh | Procede cosmetique pour realiser un modelage corporel au moyen d'un agent de protection solaire et ensemble de modelage |
CN1960723B (zh) * | 2004-05-28 | 2010-09-08 | 科学发展实验室 | 烷基呋喃在制备用于治疗肥胖症的药物中的用途 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2856294B1 (fr) | 2003-06-18 | 2005-08-05 | Expanscience Lab | Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite |
US20070232698A1 (en) * | 2004-05-31 | 2007-10-04 | Akira Shibuya | Slimming Skin External Preparation and Cosmetic Containing the Same |
DE102005032237A1 (de) * | 2005-07-07 | 2007-01-11 | Beiersdorf Ag | Emulgatorkombination für Kosmetika |
US20110274715A1 (en) * | 2008-05-22 | 2011-11-10 | Melissa France | Methods and compositions for cooling the human body |
FR2969494B1 (fr) * | 2010-12-22 | 2013-11-08 | Expanscience Lab | Extrait de parties aeriennes de gynandropsis gynandra ou cleome gynandra et compositions cosmetiques, dermatologiques le comprenant |
KR101358718B1 (ko) * | 2011-06-10 | 2014-02-10 | 연세대학교 산학협력단 | 피마자 추출물 및 괴화 추출물을 유효성분으로 포함하며, 셀룰라이트 개선 효과가 있는 화장료 조성물 |
CN102488210B (zh) * | 2011-12-27 | 2013-06-19 | 西南大学 | 染料木素水凝胶的复合物及其制备方法 |
CN105520880A (zh) * | 2016-01-20 | 2016-04-27 | 广州丹奇日用化工厂有限公司 | 瘦身化妆品组合物 |
CN115245470A (zh) * | 2021-04-27 | 2022-10-28 | 山东本真化妆品有限公司 | 水包油乳液及其在对抗婴儿湿疹中的用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0829261A2 (fr) * | 1996-09-13 | 1998-03-18 | Director General of Shikoku National Agricultural Experiment Station, Ministry of Agriculture, Forestry and Fisheries | Composition contenant de l'isoflavone ou ses derives pour promouvoir la degradation de graisse dans des cellules de graisse |
WO1999047118A1 (fr) * | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Compositions pour modifier l'aspect exterieur de la peau |
DE10009423A1 (de) * | 2000-02-28 | 2001-09-06 | Henkel Kgaa | Kosmetische und pharmazeutische Zubereitungen |
WO2001064177A1 (fr) * | 2000-02-28 | 2001-09-07 | Henkel Kommanditgesellschaft Auf Aktien | Utilisation de flavones ou d'isoflavones pour le traitement de la cellulite |
WO2001074345A2 (fr) * | 2000-03-31 | 2001-10-11 | Jonathan Ingram | Isoflavones utilises pour traiter l'obesite |
FR2822068A1 (fr) * | 2001-03-15 | 2002-09-20 | Pharmascience Lab | Composition topique comprenant une association de lipides furanniques d'avocat et d'isoflavones |
US20020160064A1 (en) * | 2001-02-26 | 2002-10-31 | Fred Zulli | Cosmetics containing isoflavone aglycones |
WO2002087700A1 (fr) * | 2001-04-26 | 2002-11-07 | The Procter & Gamble Company | Methode, necessaire et dispositif de traitement cosmetique d'etats cutanes |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20011182A1 (it) * | 2001-06-05 | 2002-12-05 | Indena Spa | Composizioni farmaceutiche e/o cosmetiche per il trattamento di adiposita' localizzate e della cellulite |
-
2002
- 2002-06-27 FR FR0207995A patent/FR2841470B1/fr not_active Expired - Fee Related
-
2003
- 2003-06-25 MX MXPA05000073A patent/MXPA05000073A/es active IP Right Grant
- 2003-06-25 WO PCT/FR2003/001956 patent/WO2004002435A2/fr active IP Right Grant
- 2003-06-25 ES ES03761638T patent/ES2311730T3/es not_active Expired - Lifetime
- 2003-06-25 EP EP03761638A patent/EP1515696B1/fr not_active Expired - Lifetime
- 2003-06-25 CN CNA038180170A patent/CN1671354A/zh active Pending
- 2003-06-25 AU AU2003264673A patent/AU2003264673A1/en not_active Abandoned
- 2003-06-25 CA CA002491150A patent/CA2491150A1/fr not_active Abandoned
- 2003-06-25 US US10/519,096 patent/US20050256061A1/en not_active Abandoned
- 2003-06-25 DE DE60322898T patent/DE60322898D1/de not_active Expired - Lifetime
-
2005
- 2005-09-23 HK HK05108441A patent/HK1074404A1/xx not_active IP Right Cessation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0829261A2 (fr) * | 1996-09-13 | 1998-03-18 | Director General of Shikoku National Agricultural Experiment Station, Ministry of Agriculture, Forestry and Fisheries | Composition contenant de l'isoflavone ou ses derives pour promouvoir la degradation de graisse dans des cellules de graisse |
WO1999047118A1 (fr) * | 1998-03-16 | 1999-09-23 | The Procter & Gamble Company | Compositions pour modifier l'aspect exterieur de la peau |
DE10009423A1 (de) * | 2000-02-28 | 2001-09-06 | Henkel Kgaa | Kosmetische und pharmazeutische Zubereitungen |
WO2001064177A1 (fr) * | 2000-02-28 | 2001-09-07 | Henkel Kommanditgesellschaft Auf Aktien | Utilisation de flavones ou d'isoflavones pour le traitement de la cellulite |
WO2001074345A2 (fr) * | 2000-03-31 | 2001-10-11 | Jonathan Ingram | Isoflavones utilises pour traiter l'obesite |
US20020160064A1 (en) * | 2001-02-26 | 2002-10-31 | Fred Zulli | Cosmetics containing isoflavone aglycones |
FR2822068A1 (fr) * | 2001-03-15 | 2002-09-20 | Pharmascience Lab | Composition topique comprenant une association de lipides furanniques d'avocat et d'isoflavones |
WO2002087700A1 (fr) * | 2001-04-26 | 2002-11-07 | The Procter & Gamble Company | Methode, necessaire et dispositif de traitement cosmetique d'etats cutanes |
Non-Patent Citations (2)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 1998, no. 09 (C, & JP 10 087486 A (SEKIYA KEIZO), 7 avril 1998 (1998-04-07) * |
SCHMIDT ET AL.: "Genistein, a new cosmetic ingredient derived from soy" SÖFW-JOURNAL, vol. 127, no. 10, 12 octobre 2001 (2001-10-12), pages 22-27, XP002235454 DE * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4842260B2 (ja) * | 2004-05-28 | 2011-12-21 | ラボラトワール エクスパンシアンス | 肥満の治療および太りすぎの美容的処置用の薬剤を製造するためのフランアルキルの使用 |
WO2005117827A1 (fr) * | 2004-05-28 | 2005-12-15 | Laboratoires Expanscience | Utilisation d’alkyle furannes pour le traitement cosmetique de la cellulite |
WO2005117857A1 (fr) * | 2004-05-28 | 2005-12-15 | Laboratoires Expanscience | Utilisation d’alkyle furannes pour la preparation d'un medicament destine au traitement de l’obesite et pour le traitement cosmetique de la surcharge ponderale |
JP2008501004A (ja) * | 2004-05-28 | 2008-01-17 | ラボラトワール エクスパンシアンス | 肥満の治療および太りすぎの美容的処置用の薬剤を製造するためのフランアルキルの使用 |
US7589121B2 (en) | 2004-05-28 | 2009-09-15 | Laboratoires Expanscience | Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight |
US8859617B2 (en) | 2004-05-28 | 2014-10-14 | Laboratoires Expanscience | Use of furan alkyl for preparing an antidiabetic drug |
CN1960723B (zh) * | 2004-05-28 | 2010-09-08 | 科学发展实验室 | 烷基呋喃在制备用于治疗肥胖症的药物中的用途 |
US7872043B2 (en) | 2004-05-28 | 2011-01-18 | Laboratories Expanscience | Use of furan alkyls for a cellulite cosmetic treatment |
WO2006076240A2 (fr) * | 2005-01-10 | 2006-07-20 | The Procter & Gamble Company | Compositions, produits et methodes destines a combattre la surcharge ponderale chez un mammifere |
WO2006076240A3 (fr) * | 2005-01-10 | 2006-10-19 | Procter & Gamble | Compositions, produits et methodes destines a combattre la surcharge ponderale chez un mammifere |
FR2870740A1 (fr) * | 2005-03-21 | 2005-12-02 | Expanscience Sa Lab | Utilisation d'alkyle furannes pour le traitement cosmetique de la cellulite |
FR2870743A1 (fr) * | 2005-03-21 | 2005-12-02 | Expanscience Sa Lab | Utilisation d'alkyle furannes pour la preparation d'un medicament destine au traitement de l'obesite et pour le traitement cosmetique de la surcharge ponderale |
WO2006117392A3 (fr) * | 2005-05-04 | 2007-03-22 | Lancaster Group Gmbh | Procede cosmetique pour realiser un modelage corporel au moyen d'un agent de protection solaire et ensemble de modelage |
US7731942B2 (en) | 2005-05-04 | 2010-06-08 | Coty Prestige Lancaster Group Gmbh | Cosmetic treatment for body-modelling with sun protection and modelling kit |
Also Published As
Publication number | Publication date |
---|---|
ES2311730T3 (es) | 2009-02-16 |
WO2004002435A3 (fr) | 2004-05-13 |
US20050256061A1 (en) | 2005-11-17 |
AU2003264673A8 (en) | 2004-01-19 |
MXPA05000073A (es) | 2005-09-30 |
DE60322898D1 (de) | 2008-09-25 |
EP1515696B1 (fr) | 2008-08-13 |
HK1074404A1 (en) | 2005-11-11 |
CN1671354A (zh) | 2005-09-21 |
CA2491150A1 (fr) | 2004-01-08 |
FR2841470B1 (fr) | 2006-01-13 |
AU2003264673A1 (en) | 2004-01-19 |
EP1515696A2 (fr) | 2005-03-23 |
FR2841470A1 (fr) | 2004-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1064931B1 (fr) | Composition cosmétique comprenant au moins un hydroxystilbene et de l'acide ascorbique | |
EP1648569B1 (fr) | Utilisation cosmetique d'une composition comprenant au moins une oxazoline, a titre de principe actif, comme amincissant et/ou pour prevenir et/ou traiter la cellulite | |
EP1039878B1 (fr) | Utilisation des compositions cosmetiques contentant au moins une auxine | |
EP1515696B1 (fr) | Utilisation d'isoflavones pour favoriser l'amincissement | |
FR2777186A1 (fr) | Utilisation d'au moins un hydroxystilbene dans une composition raffermissante | |
EP0938891A1 (fr) | Composition cosmétique contenant de l'acide cinnamique ou de ses dérivés et son utilisation | |
WO2003002088A2 (fr) | Utilisation d'une huile de graines de cucurbitacees pour inhiber l'activite de la 5alpha-reductase | |
WO2012172199A1 (fr) | Composition a base de camellia japonica et polygonum hydropiper pour protection de la peau | |
EP0946138B1 (fr) | Utilisation d'un extrait de potentilla erecta dans le domaine de la cosmetique et de la pharmacie | |
CA2407294A1 (fr) | Extrait de vegetal de l'espece olea europaea comme inhibiteur de no-synthase et utilisations | |
FR2818148A1 (fr) | Composition,notamment cosmetique, renfermant, la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoide | |
WO2005094776A1 (fr) | Compositions cosmetiques ou dermatologiques et leurs applications | |
FR2926021A1 (fr) | Utilisation de derives c-glycoside a titre d'actif vasculaire | |
EP1768684A1 (fr) | Composition comprenant un extrait de lotus bleu a effet decontractant de la peau | |
EP0925779B1 (fr) | Composition cosmétique contenant de l'acide cinnamique ou d'au moins l'un de ses dérivés et son utilisation | |
EP2229145A2 (fr) | Utilisation d'un extrait de petales de coquelicot pour la nutrition de l'epiderme | |
FR2871382A1 (fr) | Composition comprenant un complexe d'extraits vegetaux, a effet decontractant de la peau | |
FR2827762A1 (fr) | Utilisation de steroides comme amincissants | |
FR2876912A1 (fr) | Nouvelle utilisation de guggulipides en therapeutique et en cosmetique | |
FR2828402A1 (fr) | Composition cosmetique ou dermatologique comprenant une association de l'igf1 et/ou d'un compose mimetique de l'igf1 et au moins un isoflavonoide | |
FR2828400A1 (fr) | Composition cosmetique ou dermatologique comprenant une association entre de l'igf1 et/ou un compose mimetique de l'igf1, et au moins un retinoide et/ou au moins un derive de retinoide | |
FR2986966A1 (fr) | Composition cosmetique et/ou dermatologique contenant des activateurs de sirtuines | |
FR2818138A1 (fr) | Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un agent depigmentant | |
FR2871381A1 (fr) | Composition comprenant un extrait vegetal a effet decontractant de la peau | |
FR2818137A1 (fr) | Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins une vitamine et/ou un co-facteur enzymatique |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10519096 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2491150 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/A/2005/000073 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003761638 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038180170 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003761638 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: JP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2003761638 Country of ref document: EP |